Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
Why now
Thesis: Novo falls 7% despite $23B obesity sales target
Catalyst to watch: Guidance detail or trial updates
Main risk: Expectations already priced high
Why it matters
A 7% drop despite a large sales target suggests guidance or expectations disappointed relative to already high obesity-drug optimism.
Sources
- cnbc · 2026-09-21 08:31 UTC